NEW YORK (AP) — Forest Laboratories Inc. said Tuesday its net income dropped 79 percent in the fiscal first quarter after its antidepressant Lexapro lost patent protection, allowing other companies to sell low-cost versions of the drug.
Generic versions of Lexapro went on sale in February and March, and Forest's revenue from the drug plunged 81 percent in the first quarter, to $110 million. The company said in June that the competing generics were selling for lower prices than it had expected, and they were also taking a slightly larger share of the market than Forest had projected. Forest still sells the brand name version of Lexapro, and it gets some revenue from sales of Mylan Inc.'s company-approved generic.
Forest also reported greater costs related to the sales of drugs it launched in 2011.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
